Close Menu
    Trending
    • American Businessman Mark Eric Williams Vindicated in Six-Year, US$150 Million-Plus Litigation Brought by Kuwaiti State Entities
    • Air Arabia Egypt launches Cairo to Al Ain flights soon
    • TÜV SÜD opens its International Technology & Innovation Campus in the Guangdong-Hong Kong-Macao Greater Bay Area
    • Huawei Unveils Financial AI Scaling Capabilities at Singapore FinTech Festival 2026
    • Botswana opens consultations on proposed 33 percent hike now
    • UnionPay International and Transsion Announce Global Partnership to Bring UnionPay Payments to T Wallet, Debuting in Pakistan
    • Lianlian DigiTech Launches LianLian XWorker, an AI Workforce Platform for Global Commerce
    • PM Modi meets Prince and Princess of Wales for climate talks
    Friday, November 20
    UAE TribuneUAE Tribune
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    UAE TribuneUAE Tribune
    Home » New study highlights potential of Pfizer’s oral weight loss drug as alternative to Ozempic
    Health

    New study highlights potential of Pfizer’s oral weight loss drug as alternative to Ozempic

    May 22, 2023
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    A peer-reviewed study released on Monday reveals that an oral weight loss drug developed by Pfizer demonstrates similar efficacy and faster results compared to Novo Nordisk’s Ozempic injection. The phase two clinical trial included 411 adults with Type 2 diabetes who were either given Pfizer’s pill, danuglipron, twice a day or a placebo. The study found that patients who took a 120-milligram dosage of danuglipron lost an average of 10 pounds (4.60 kilograms) over a 16-week period.

    New study highlights potential of Pfizer's oral weight loss drug as alternative to Ozempic

    In comparison, a phase three clinical trial on Ozempic showed that adults using a 1-milligram injection lost an average of 9.9 pounds (4.53 kilograms) over 30 weeks. The results suggest that Pfizer’s drug may be equally effective for weight loss as Ozempic, while offering the advantage of being an oral treatment option rather than an injection. Both danuglipron and Ozempic are glucagon-like peptide-1 antagonists, belonging to a class of drugs that mimic a gut hormone called GLP-1, signaling fullness to the brain. These drugs are also beneficial in managing Type 2 diabetes by promoting insulin release and reducing blood sugar levels.

    Pfizer’s entry into the weight loss drug market comes as Novo Nordisk’s Ozempic and Wegovy have gained attention for their weight loss effects. These drugs have been sought after by celebrities, social media influencers, and even Elon Musk for shedding unwanted weight. However, concerns have been raised about the perpetuation of a dangerous diet culture that prioritizes weight loss and thinness. Additionally, some patients who discontinue these drugs experience difficulty in controlling weight rebound.

    With over 2 in 5 adults having obesity and 1 in 11 adults having severe obesity, the search for effective weight loss solutions has become a priority for public health authorities and pharmaceutical companies. Pfizer’s promising results from the clinical trial provide hope for an alternative oral treatment option that could potentially address the global obesity epidemic more conveniently. Further research and development will be necessary to assess the long-term effectiveness and safety of Pfizer’s weight loss drug and its potential impact on individuals struggling with obesity.

    Related Posts

    Ebola adds 60 cases in a day as Congo deaths hit 5,568

    November 18, 2026

    Ebola cases top 11,200 as Africa CDC warns of record outbreak

    November 16, 2026

    Yellow fever kills 18 across nine African nations, WHO says

    November 7, 2026

    Dengue kills 173 in October as Bangladesh toll climbs to 418

    November 2, 2026

    Ebola death toll in DR Congo nears 4,900 as cases pass 10,000

    October 28, 2026

    Malaria kills 22 in Namibia’s Zambezi Region as cases rise

    October 26, 2026
    Latest News

    Air Arabia Egypt launches Cairo to Al Ain flights soon

    November 20, 2026

    Botswana opens consultations on proposed 33 percent hike now

    November 19, 2026

    PM Modi meets Prince and Princess of Wales for climate talks

    November 19, 2026

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026

    Dubai Airports expects over 70 million guests in 2026

    November 18, 2026

    Ebola adds 60 cases in a day as Congo deaths hit 5,568

    November 18, 2026

    Prabowo says DEFA can unlock $2 trillion ASEAN digital economy

    November 18, 2026

    Over 9 million visitors lift Tunisia tourism income 3.4%

    November 17, 2026
    © 2026 UAE Tribune | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.